SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/054DB6AD4CA7B3123994E8E6203F21A7634A2801CEC6D9343D71DD7C88EE479C3350106BB2F11F6041F3B450F74D8ABF>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/054DB6AD4CA7B3123994E8E6203F21A7634A2801CEC6D9343D71DD7C88EE479C3350106BB2F11F6041F3B450F74D8ABF
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/054DB6AD4CA7B3123994E8E6203F21A7634A2801CEC6D9343D71DD7C88EE479C3350106BB2F11F6041F3B450F74D8ABF
http://www.w3.org/2000/01/rdf-schema#comment
"In this study we uncovered activating mutations in CSF1R and rearrangements in RET and ALK that conferred dramatic responses to selective inhibition of RET (selpercatinib) and crizotinib respectively in patients with histiocytosis."
xsd:string
http://purl.uniprot.org/uniprot/#_8573253867F08DD2602A61DE3BB8271F2697E6DD5707E34672EAFE62E7B533648AB743BF789CDA7C7F826C69DD6F2498
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/054DB6AD4CA7B3123994E8E6203F21A7634A2801CEC6D9343D71DD7C88EE479C3350106BB2F11F6041F3B450F74D8ABF
http://purl.uniprot.org/uniprot/D1MAM1
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/054DB6AD4CA7B3123994E8E6203F21A7634A2801CEC6D9343D71DD7C88EE479C3350106BB2F11F6041F3B450F74D8ABF
http://purl.uniprot.org/uniprot/#_D1MAM1-mappedCitation-31768065
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/054DB6AD4CA7B3123994E8E6203F21A7634A2801CEC6D9343D71DD7C88EE479C3350106BB2F11F6041F3B450F74D8ABF